One CJC-1295 with DAC injection kept GH elevated for at least 6 days

What is CJC-1295 with DAC?

CJC-1295 with DAC is a modified GHRH(1-29) analog carrying a maleimidopropionyl group, the "drug affinity complex," that tethers it to albumin. After injection, that group forms a covalent thioether bond with circulating albumin.

Native GHRH has a half-life measured in minutes. Tethering the analog to albumin, a protein the body recycles slowly, stretches that half-life to days. The version sold without the albumin tether is covered in the CJC-1295 No DAC evidence review.

Does CJC-1295 with DAC work in animals?

CJC-1295 with DAC works as designed in rodents: in rats, the albumin-bound conjugate produced four times the GH area-under-curve of native hGRF(1-29) ^[3]. The conjugate stayed detectable in plasma past 72 hours, which confirmed both the binding chemistry and that the conjugate still activates the pituitary GHRH receptor ^[3].

In GHRH-knockout mice, daily dosing fully normalized body weight, length, and bone growth over five weeks, with evidence of somatotroph cell proliferation ^[4]. Less frequent dosing only partially normalized growth ^[4].

The animal story is mechanistically coherent: the receptor agonism works, and the albumin tether extends exposure. It does not establish what sustained exposure does in a healthy adult with normal pituitary function, over months rather than weeks, on top of the body's own GH pulses. That gap runs through every benefit claimed for CJC-1295 with DAC.

Does CJC-1295 with DAC raise GH in humans?

CJC-1295 with DAC reliably raises GH and IGF-1 in healthy adults. The two human trial reports cited below both come from the same 2006 development effort, both studied healthy volunteers, and neither was designed to measure a clinical outcome.

Teichman and colleagues combined a single-dose escalation study with a multiple-dose cohort (n≈65 total). After one injection, GH rose in a dose-dependent way for 6+ days and IGF-1 stayed elevated for 9-11 days, with no serious adverse events reported over the study period ^[1].

The Teichman trial is the one cited constantly as proof that CJC-1295 "works." It proves the compound raises two blood biomarkers. It says nothing about body composition, strength, recovery, or sleep architecture, because it measured none of them.

Does CJC-1295 with DAC preserve natural GH pulses?

Yes, on top of a raised floor: one week after a single CJC-1295 DAC injection, GH pulses persisted while trough GH sat 7.5-fold higher ^[2]. Ionescu and colleagues also found IGF-1 up 45% at that point ^[2].

The finding cuts both ways, and most coverage skips it. CJC-1295 with DAC does not flatten GH into a continuous line with no pulses; the pulses persist. But the trough between pulses, the low point the body normally returns to before the next pulse fires, was elevated 7.5-fold. That is a materially different exposure pattern from native physiology.

Does stacking CJC-1295 with DAC and a GHRP make sense?

Not cleanly: CJC-1295 with DAC keeps GH and IGF-1 elevated between pulses, which works against the low baseline a GHRP is designed to fire from ^[2]. "Stack with a GHRP for pulsatile synergy" protocols ignore the elevated trough.

A GHRP is designed to trigger a pulse from a low, near-zero trough, the physiologic norm. DAC's job is to make sure that baseline is never low again for days at a time. What studies show for CJC-1295 and ipamorelin covers a related stack.

Does CJC-1295 with DAC cause fat loss or muscle gain?

No published human trial has measured fat loss or lean mass change with CJC-1295 with DAC, at any dose, in any population. The one trial that could have produced an efficacy readout, a Phase 2 study in HIV-associated visceral obesity, was registered, then terminated, and never published.

That leaves zero completed trials behind every downstream benefit claim: fat loss, lean mass, recovery, and sleep. For contrast, see the tesamorelin visceral fat evidence in lipodystrophy.

Preclinical work supports the receptor mechanism and shows growth normalization in GH-deficient rodents ^[3]⁠^[4]. Growth-axis normalization in a knockout mouse is not evidence for fat loss or lean mass gain in an adult human with an intact pituitary. The two are related by mechanism, not by data.

CJC-1295 with DAC grades D for that reason. The mechanism and the biomarker response are well characterized, and the outcomes people take it for are entirely unstudied.

What is the half-life of CJC-1295 with DAC?

CJC-1295 with DAC has a half-life of 5.8 to 8.1 days, from the pharmacokinetic data, and that figure is the strongest number in its literature ^[1]. The half-life is a legitimate basis for infrequent dosing schedules. It is not a basis for claims about what that dosing accomplishes downstream.

Forum protocols commonly describe 1-2 mg weekly doses. That convention comes from practitioner and forum consensus, not from a published dose-response efficacy trial, and it deserves the weight of consensus rather than trial data.

What is still unknown about long-term CJC-1295 with DAC use?

Long-term CJC-1295 with DAC use is unstudied: no published data extend past a few weeks of exposure. The open questions are specific:

• Antibodies. Sustained exposure to a modified peptide is the kind of stimulus that can provoke an immune response against the native hormone it resembles. The concern was flagged in the original trial population, which was studied for weeks, not the months or years many current users report. No one has published follow-up data on whether that risk grows with duration of use.
• Insulin sensitivity and growth signaling. No data describe what a continuously elevated GH trough does to insulin sensitivity or tissue growth signaling over a year or more. Theoretical concerns about both are reasonable given sustained IGF-1 elevation.
• Cardiovascular outcomes. No published cardiovascular outcome data exist, despite a cardiac-event signal flagged by regulatory sources.
• Vial contents. CJC-1295 with DAC is sold research-use-only through unregulated channels, so nothing independently verifies that a vial matches the labeled sequence or purity. Even the biomarker response people track at home starts from that unverified assumption.

The half-life extension DAC provides is real, well characterized, and convenient. It is also the feature with the least human data behind the benefits attributed to it. Sustained GH and IGF-1 elevation is a documented biomarker fact. Whether sustained elevation, as opposed to the pulsatile pattern the body uses, produces the fat loss, muscle gain, or recovery people are chasing has never been tested in a published human trial.